Immune Checkpoint Inhibitor-induced Bilateral Vestibulopathy
Koch EA, Nickel FT, Heinzerling L, Schulz YK, Berking C, Erdmann M (2021)
Publication Type: Journal article
Publication year: 2021
Journal
DOI: 10.1097/CJI.0000000000000353
Abstract
Checkpoint inhibitors (CPI), such as anti-programmed death-1 and anti-cytotoxic T-lymphocyte antigen-4antibodies cause serious, rarely fatal immune-related adverse events (irAE) potentially in all organ systems. Neurological immune-related adverse events occur in 1%-5% of patients on CPI therapy and may present with dramatic clinical symptoms of the sensory organs. After exclusion of other causes, a high-dose treatment with corticosteroids is crucial for clinical outcome with lower risk of sequelae. We present a severe case of CPI-related ongoing and most likely irreversible bilateral vestibular affection. A 59-year-old male melanoma patient with brain metastasis undergoing immunotherapy with anti-cytotoxic T-lymphocyte antigen-4 and anti-programmed death-1 antibodies developed severe debilitating rotatory vertigo. Bilateral vestibulopathy was diagnosed as a result of the CPI therapy after a thorough analysis including magnetic resonance imaging, laboratory tests of blood and cerebrospinal fluid as well as neurological and otorhinolaryngology examinations. The vertigo improved slightly during a 10-day course of steroid therapy and intensive balance training but did not resolve completely.
Involved external institutions
Germany (DE)How to cite
APA:
Koch, E.A., Nickel, F.T., Heinzerling, L., Schulz, Y.K., Berking, C., & Erdmann, M. (2021). Immune Checkpoint Inhibitor-induced Bilateral Vestibulopathy. Journal of Immunotherapy. https://doi.org/10.1097/CJI.0000000000000353
MLA:
Koch, Elias A.T., et al. "Immune Checkpoint Inhibitor-induced Bilateral Vestibulopathy." Journal of Immunotherapy (2021).
BibTeX: Download